Сlinical Trials

The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.
 

Completed phase I/IIa clinical trial

Twenty-seven patients participated in phase I/IIa clinical trials conducted in 4 different clinical centers in Eurasia.

A high degree of safety was demonstrated in dose escalation studies.

Three groups of five patients each were administered escalating doses of Elenagen. Only minimal Grade I side effects were observed in some patients.

Elenagen was able to reduce and outright cease disease progression

in patients with melanoma, breast, ovary, lung, and renal cancer. Patients admitted into our trial were “salvage patients” who have failed all other available treatment protocols and were in the active disease progression stage. The main goal was to stop the disease progression, which we have achieved.

Restoring tumor sensitivity to chemotherapy.

All patients admitted to the clinical trials already failed multiple previous lines of chemotherapy. However, after treatment with Elenagen, the patients were able to successfully respond to new rounds of chemotherapy.

Elenagen: Case Study

Patient background

✓
A 48-year old female with triple-negative and BRCA1/2-negative breast cancer was administered to a hospice.
✓
Active disease progression after 21 courses of chemotherapy
✓
Impaired quality of life
✓
Limited ability to wear clothing due to metastatic lesions on the skin
✓
Severe painkillers interfering with normal cognition

Treatment

✓
Elenagen was applied intramuscularly at a dose of 2.5 mg weekly in combination with standard chemotherapy scheme CMF (cyclophosphamide, methotrexate, fluorouracil)

Result

✓
Partial tumor regression (by 33%)
✓
19 weeks of progression-free survival
✓
Increase of quality of life
✓
Limited use of painkillers leading to complete recovery of cognition mode
✓
Only limited discomfort due to the skin lesions
✓
The patient retuned from a hospice to home

US Clinical Trials

✓
Randomized case-control phase II clinical studies
✓
The goal: to test the ability of Elenagen to enhance standards of care for
  • Triple negative breast cancer
  • Ovarian cancer
  • Inoperable stomach cancer
  • Pancreatic cancer
✓
Observation by the leading US medical centers
✓
Pending future international clinical trials in
  • Glioblastoma
  • Metastatic hormone-resistant prostate cancer
  • Metastatic renal cancer
  • Metastatic uterus cancer
  • Melanoma

Ex-US Clinical Trials

Anticipated to begin in 2024

The goal: to test the ability of Elenagen to enhance standards of care for

  • Triple negative breast cancer
  • Ovarian cancer

For any inquiries, please contact: info@curelab.com